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Abstract
A method for quickly screening and identifying dominant B cell epitopes was developed using hepatitis B virus
(HBV) surface antigen as a target. Eleven amino acid fragments from HBV surface antigen were synthesized by
9-fluorenylmethoxy carbonyl solid-phase peptide synthesis strategy, and then CdTe quantum dots were used to
label the N-terminals of all peptides. After optimizing the factors for fluorescence polarization (FP) immunoassay,
the antigenicities of synthetic peptides were determined by analyzing the recognition and combination of
peptides and standard antibody samples. The results of FP assays confirmed that 10 of 11 synthetic peptides
have distinct antigenicities. In order to screen dominant antigenic peptides, the FP assays were carried out to
investigate the antibodies against the 10 synthetic peptides of HBV surface antigen respectively in 159 samples
of anti-HBV surface antigen-positive antiserum. The results showed that 3 of the 10 antigenic peptides may be
immunodominant because the antibodies against them existed more widely among the samples and their antibody
titers were higher than those of other peptides. Using three dominant antigenic peptides, 293 serum samples were
detected for HBV infection by FP assays; the results showed that the antibody-positive ratio was 51.9% and the
sensitivity and specificity were 84.3% and 98.2%, respectively. In conclusion, a quantum dot-based FP assay is a very
simple, rapid, and convenient method for determining immunodominant antigenic peptides and has great potential
in applications such as epitope mapping, vaccine designing, or clinical disease diagnosis in the future.
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Background
An epitope or antigenic determinant is the core part of
antigen involved in the recognition with an antibody.
After antigens, containing numerous epitopes, are
recognized by the human immunological system, B lym-
phocytes will synthesize and secrete miscellaneous anti-
bodies targeting different epitopes to mediate further
immunological process. Nowadays, there are many
methods that are used to investigate and confirm antigen
epitopes, for example, proteolytic cleavage of antigen-
monoclonal antibody complexes, proteolytic or chemical
cleavage fragment method, Western blotting, PEPSCAN
method, chemical modification or mutation analyses,
chemosynthesis of peptide, surface display of peptide li-
braries and random fragment expression libraries, X-ray
crystallographic assay and nuclear magnetic resonance
spectroscopy assay, and so on [1]. However, most of
these methods are complicated, difficult to perform, or
of low efficiency. With the development of computer
technology and bioinformatics, a set of methods for epi-
tope prediction were developed based on the structural
property of amino acid sequences [2]; the accuracy of
prediction of antigenic determinants is about 75% [3].
The methods for epitope prediction can reduce the
range of possible epitope and bring us much less work-
loads for epitope screening. However, it is possible that
some of the predicted epitopes exhibit no strong antige-
nicity. So, developing a novel method to analyze the
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antigenicity of predicted peptides has become an urgent
requirement for epitope determination.
Fluorescence polarization (FP) is a unique and power-
ful technique for the rapid analysis of interactions
of small molecular weight molecules (labeled with
fluorophore) and macromolecules. The theory of fluor-
escence polarization was for the first time described in
1926 by Perrin [4]. When fluorescent molecules in solu-
tion are excited by a plane-polarized light beam with an
appropriate wavelength, they emit fluorescent signals
back into the same polarized plane, provided that the
molecules remain stationary. However, if the excited
molecules rotate or tumble while in the excited state,
then fluorescence is emitted into a plane different from
the plane used for excitation. Therefore, if the viscosity
and temperature of a solution are kept constant, the de-
gree of fluorescence polarization is dependent on the
molecular volume, that is, the size of a fluorescent mol-
ecule. FP assay is based on the rotational differences be-
tween a small soluble molecule in solution (labeled with
a fluorochrome) and the small molecule combined with
its ligand. A small molecule can rotate randomly at a
rapid rate, resulting in rapid depolarization of light, while a
larger complex molecule can rotate slower and depolarize
light at a reduced rate. The rate change in depolarization
can be measured. High polarization values indicate that the
small molecule is reacting with its ligand or target mol-
ecule, and low values mean that there is no small molecule
ligand or small molecule to react with target molecule.
Nowadays, homogeneous FP assays have been successfully
applied to many research fields, including DNA-protein,
protein-protein, and antigen-antibody binding [5-11].
However, the current FP assay is based on organic dye la-
beling, having some problems such as intrinsic photo-
bleaching and low-emission efficiency, and how to solve
these questions has become a great challenge.
Quantum dots have been subject to intensive investiga-
tions due to their unique properties and potential appli-
cation prospect [12-14]. So far, several methods have
been developed to synthesize water-soluble quantum dots
(QDs) for use in biologically relevant studies [15-18]. QDs
exhibit high quantum yield, high photostability, and size-
dependent tunable emission, being attractive alternative lu-
minescent labels for ultrasensitive detection and molecular
imaging. For example, QDs have been used successfully in
cellular imaging [19,20], immunoassays [21], DNA
hybridization [22], and optical barcoding [23]. Quantum
dots provide a new functional platform for bioanalytical
sciences and biomedical engineering. Therefore, it is feas-
ible to use QD labeling to improve the FP technique for
detection of tumor biomarkers in patient sera [24,25].
If micromolecular antigens are adopted, FP assays can
also be used to analyze the interaction of the antigen
and its antibody. Herein, we reported a CdTe quantum
dot-based method to screen rapidly antigenic epitopes.
All possible antigenic epitopes from hepatitis B virus
(HBV) surface antigen protein were predicted, and the
antigenicity of peptide was determined by analyzing the
recognition and combination of peptide and standard
antibody samples using the FP technique. Subsequently,
the immunodominant epitopes of HBV surface antigen
in Chinese people with positive anti-HBV surface anti-
gen were screened using the same method. Besides, the
application of the obtained dominant antigenic peptides
in detecting anti-HBV surface antibody was also investi-
gated by FP assay.
Methods
Peptide sequence design
Candidate peptides were designed based on the pre-
dicted results of epitope analysis programs: the second
structure of the HBV surface antigen protein sequences
(UniProtiKB/Swiss-Prot: Q913A6) was predicted by the
Chou-Fasman method [26], the flexible regions were an-
alyzed by the Karplus-Schulz method [27], the hydro-
philic regions were predicted by the Kyte-Doolittle
method [28], the surface probability was analyzed by the
Emini method [29], the antigenic index was analyzed by
the Jameson-Wolf method [30], and the antigenic deter-
minants were predicted by the Kolaskar-Tongaonkar
method [3]. After comparing these multiple-parameter
assay results, 11 amino acid fragments from the HBV
surface antigen protein were chosen as possible epitopes.
These peptides are summarized in Table 1.
Synthesis of antigenic peptides
All peptides were synthesized on 2-chlorotrityl chloride
resin (1.6 mmol/g) using the standard solid-phase method
of 9-fluorenylmethoxy carbonyl (Fmoc) chemistry [31].
Peptides were produced on a 0.2-mmol scale, and Fmoc-
Table 1 Designed antigenic peptide sequences from HBV
surface antigen protein
No. of peptides Amino acid sequences Location in HBV surface
antigen protein
1 TNLSVPNPLGFFPDHQLDP 14 to 32
2 NKVGVGA 56 to 62
3 PHGGLLGW 70 to 77
4 QAQGLLTTVPAAPP 80 to 93
5 PTPFSPPLRD 105 to 114
6 QDSRVRALYLPA 132 to 143
7 SSGTVSPAQNTVSAISSI 147 to 164
8 GGTPACPG 217 to 224
9 SQISSHSPTCCPPICPGYRW 229 to 248
10 STGPCKTCTT 291 to 300
11 MFPSCCCT 307 to 314
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preactivated amino acids as pentafluorophenyl esters were
used for the coupling reactions in the presence of
hydroxybenzotriazole (Sigma Chemical Co., St. Louis, MO,
USA) in dimethylformamide (DMF). Excess amino acids
were used throughout the synthesis. Chain elongation reac-
tion was performed followed by Fmoc deprotection in 20%
piperidine in DMF.
When the chain elongation reaction was finished,
the Fmoc protecting groups were removed from the
N terminus of the peptides by 25% piperidine in
DMF followed by washing with DMF for four times.
Following washing for four times with DMF and
dichloromethane, the resin was dried under vacuum.
Subsequently, the as-prepared peptides were cleaved
from the resin using standard trifluoroacetic acid
(TFA) cleavage procedures in TFA with 5% H2O
followed by multiple ether extractions. All synthetic
peptides were purified to >95% by reverse-phase
high-pressure liquid chromatography performed with
a liquid chromatograph (Waters, Milford, MA, USA).
Peptides were analyzed by mass spectrometry to con-
firm that the desired product was obtained.
Preparation of QDs and QD-peptide conjugates
The CdTe QDs were prepared according to our previ-
ous report [32]. Briefly, 5 mmol of CdCl2·5H2O was
dissolved in 110 mL of water, and 12 mM of
thioglycolic acid (TGA) was added under stirring.
NaOH solution was used to adjust the pH of the re-
sultant solution to 11. The solution was cleared by N2
bubbling for 30 min. Under stirring, 2.5 mM of oxygen-
free NaHTe solution was injected into the solution. After
reflux at 100°C for 4 h, the TGA-capped CdTe QDs were
synthesized. The obtained QDs were purified by precipi-
tation in ethanol and redispersed in phosphate-buffered
saline (PBS; 0.2 mg/mL KCl, 1.44 mg/mL Na2HPO4,
0.24 mg/mL KH2PO4, 8 mg/mL NaCl; pH 7.4). Absorb-
ance spectrum and photoluminescence spectrum were an-
alyzed to characterize the fluorescent properties of QDs
with a PerkinElmer LS 55 spectrofluorimeter (Waltham,
MA, USA).
Afterwards, 0.5 mL of 3 mg/mL QDs and 0.5 mL of
0.8 mg/mL antigenic peptides were mixed, and then 50 μL
of 1 mg/mL EDC was added. The resulting solution
reacted at room temperature for 3 h with continuous
mixing and then stayed at 4°C for 24 h. Bovine serum albu-
min (BSA) was added into the solution at a concentration
of 1 mg/mL and incubated at room temperature for 3 h.
The QD-labeled SPAs were then centrifuged at 15,000×g
for 30 min, and the supernatant was discarded. A vol-
ume of 1.05 mL PBS with 0.5% Tween-20 (PBST;, v/v)
was used to resuspend and wash QD-labeled antigenic
peptides by centrifugation at 15,000×g for three times.
Finally, the QD-labeled conjugates were dispersed in
1.05 mL PBST and kept at 4°C for usage. Then, 1%
agarose gel electrophoresis was performed to analyze the
QD-peptide conjugates.
Standard serum samples
HBV-positive sera were collected from patients who
were confirmed by enzyme-linked immunosorbent assay
(ELISA) test. The negative sera were collected from
healthy volunteers. One hundred anti-HBV surface anti-
gen antibody-positive sera and 100 negative sera were
mixed separately at equal volume ratio. The mixtures
were used as standard antibody-positive and antibody-
negative serum samples.
Fluorescence polarization assay of QD-labeled HBV
antigenic peptide binding to standard antibody
Fluorescence polarization experiments were performed in
a black 384-well plate (MJ Research, Waltham, MA, USA)
using a Wallac Victor2 (1420 multilabel counter) fluores-
cence polarization analyzer (PerkinElmer Life Sciences).
Assays were done at room temperature using filters for
fluorescein excitation (480 nm) and emission (595 nm). To
obtain optimal concentration for fluorescence polarization
assay, QD-labeled antigenic peptides were diluted to dif-
ferent concentrations (from 0 to 2.5 nM, at intervals of
0.25 nM) in PBS, each of the samples was added to
three wells of the 384-well plate (25 μL/well), and then
the fluorescence polarization of the samples was mea-
sured. The results of the FP assay were expressed as
millipolarization (mP) values, and the experiment was
repeated three times.
To reduce the interference to FP values caused by
impurities existing in serum samples, different dilu-
tions (1:5, 1:10, 1:15 to 1:55) of standard serum sam-
ples were tested for FP assay. Serum samples were
diluted with 2.5 nM QD-labeled peptide/PBS buffer
(containing 0.2 mg/mL BSA). After thorough mixing,
the mixture was added to three wells of the 384-well
plate (25 μL/well) and incubated for 30 min before
reading. This assay was repeated to obtain the reaction
time needed for binding saturation with changed incuba-
tion time (0, 2, 5, 10, 15, 20, 25, and 30 min). The positive
standard serum, negative standard serum, and diluent
buffer blank control were included in the test.
According to optimal reaction factors, the antigenicity of
all synthetic peptides was identified by analyzing the recog-
nition and combination between peptides and standard
antibody samples using the FP method. When the peptides
bind to specific antibodies, the FP values will increase, and
the increment can express the antigenicity indirectly.
Screening for immunodominant antigenic peptides
One hundred fifty-nine samples of anti-HBV surface
antigen-positive antisera were identified by the standard
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ELISA method with commercial ELISA kits. Specific
antibodies against each peptide of HBV surface antigen
with distinct antigenicity were detected using the FP
method in all the antiserum samples. The distribution
and levels of specific antibody against each peptide were
analyzed according to the results of the FP assay.
Detecting for HBV infection by FP assay
Using the immunodominant antigenic peptides, 293
serum samples were detected for HBV infection based
on the FP assay. In order to evaluate the FP method for
detection of HBV infection, ELISA experiment was car-
ried out using a commercial ELISA kit for detection of
IgG of anti-HBV. The ELISA results were used as real
results; then, receiver operating characteristic (ROC)
curve analysis (MedCalc Software, Ostend, Belgium) was
performed on the FP assay results to determine the opti-
mal cutoff point (at which the sum of the sensitivity and
specificity values is maximal) to distinguish between
positive and negative FP assay results. The ROC curve
(a plot of the true-positive rate (sensitivity) against the
false-positive rate (100-specificity) that is obtained at
each cutoff point) was constructed, and the area under
the curve (AUC) value was calculated as a measure of
the accuracy of the test.
Results and discussion
QD conjugates and their fluorescence polarization
property
CdTe quantum dots were synthesized and characterized
by X-ray diffraction (XRD) and high-resolution transmis-
sion electron microscopy (HR-TEM; Additional file 1:
Figure S1). The QD conjugates were characterized by
spectrofluorimetry and 1% agarose electrophoresis, pre-
senting a blueshift in the maximum fluorescence wave-
length and a slow electrophoretic mobility (Figure 1).
The small molecular peptides labeled with QDs rotate
randomly at a rapid rate in solution, resulting in rapid
depolarization of light, and then, a low FP value was
measured. However, the FP value increased when the
concentration of fluorescent molecules was too low from
our report (Figure 2). The FP value was constant only
when the concentration of peptides was over 1 nmol/L.
Dilution of serum for FP assay
FP value decreases when dilution times increase either
for antibody-positive or for antibody-negative standard
serum samples, but the downtrend for the two kinds
of samples is not the same (Figure 3). These results
show that there are some other molecules in the
serum which can cause fluorescence polarization unex-
pectedly. When the dilution times are too high
(>30) or too low (<20), FP values become close for
antibody-positive and antibody-negative standard serum
samples. The margin of FP values for the two kinds of
samples reaches maximum when the serum was di-
luted to 25 times for FP assay.
Figure 1 The fluorescence emission spectrum and electrophoresis
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Figure 2 The effect of antigen concentration on FP values of
QD-labeled single-epitope synthetic peptide antigen.
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Figure 3 The FP values of diluted antibody-positive and
antibody-negative standard serum samples.
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Incubation time for FP assay
The recognition and combination of peptide and stand-
ard antibody samples are very fast. The measured FP
value becomes high when the peptides bind to their anti-
body, so the values of fluorescence polarization can rep-
resent the amount of peptide-antibody compound to
some extent. FP values increase when the incubation
time is prolonged to 10 min, but the FP values have
no obvious change even the reaction time increases
over 15 min. This shows that the reaction reaches bal-
ance after 10 to 15 min (Figure 4).
Antigenicity of synthetic peptides
The standard antibody-positive serum sample which
comprises antibodies against nearly all possible epitopes
of HBV surface antigen were used to determine the anti-
genicity of synthetic peptides. If one peptide labeled with
QDs has stronger antigenicity, more molecules of this
peptide bind to its antibody in the standard serum
sample; then, we can measure a higher FP value using
the fluorescence polarization analyzer. On the other
hand, a peptide with weaker antigenicity leads to a
lower FP value. The results of FP assay show that 10
of 11 synthetic peptides (except no. 6 peptide) have
antigenicity. When these 10 peptides reacted with stand-
ard antibody-positive serum, we measured >200-mP FP
values, which were far higher than the FP values of those
peptides that reacted with standard antibody-negative
serum (Figure 5).
Immunodominant peptides of HBV surface antigen
The dominant epitopes of HBV surface antigen were
screened by analyzing the antibody levels against 10 anti-
genic peptides in 159 anti-HBV surface antigen-positive
antiserum by FP assay. The results show that nos. 1, 10,
and 11 antigenic peptides were immunodominant among
159 samples, for the antibody levels against these pep-
tides were higher than those against other peptides or
the antibodies against these peptides widely existed
among 159 samples (Table 2).
Detection of HBV infection using immunodominant
peptides based on FP assay
The resulting three dominant antigenic peptides were
used to develop a FP-based method for detecting anti-
HBV surface antigen. After FP analysis, the FP values
represent the antibody levels against HBV surface anti-
gen. The frequency distributions of the FP assay results
obtained from the 293 serum samples are shown in
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Figure 4 Results of FP assay at different reaction times.
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HBV-negative sera had mP values of <80 and the ma-
jority of the sera from infected people had mP values
of ≥80. In order to distinguish positive and negative
results of HBV infection by FP values, all samples
were detected for HBV infection by ELISA method.
The results of ELISA were used as criterion for HBV
infection for each sample, and an optimal cutoff point
of 77 mP for FP assay was recommended by ROC
curve analysis (Figure 7). Using the FP assay method
to detect HBV infection, the results indicated that the
antibody-positive ratio was 51.9%, analyzed using the
three antigenic peptides; the sensitivity and specificity
estimates at this cutoff point were 85.4% and 98.6%,
respectively. The area under the ROC curve was 0.959
(95% confidence interval = 0.908 to 0.986), which indi-
cated a high level of accuracy for this assay.
FP assay can be used in the study of antigen-antibody
interaction, and the attachment of fluorescein to antigen
does not affect its ability to bind with an antibody. The
only limitation of the FP assay is the size of the antigen,
and the principle of FP assay restricts that only the
micromolecular antigen is suitable for interaction ana-
lysis. The more differences of molecular weight between
antigen and antibody exist, the more differences of FP
values between free antigen and antigen-antibody com-
plex can be measured. The molecular mass of synthetic
antigenic peptides is far smaller than general antigens,
so they are suitable for the screening of antigenic epi-
topes by the FP method. By investigating the interaction
between peptide and standard antibody sample, the
Figure 6 Frequency distribution of the FP assay results that were obtained from 293 serum samples. The x-axis shows the mP values, and
the y-axis shows the number of serum.
Figure 7 ROC curve obtained from the analysis of the FP
assay results of 293 serum samples. The false-positive rate
(100-specificity (x-axis)) is plotted against the true-positive rate
(sensitivity (y-axis)) for each mP cutoff point applied. An optimal
cutoff point of 77 mP is indicated (arrow). AUCROC = 0.959 (95%
confidence interval = 0.908 to 0.986).
Table 2 The results of FP assay detecting antibodies
against 10 antigenic peptides in 159 serum samples
No. of
peptides









1 5 11 90 53 129
2 29 42 79 9 67
3 19 36 88 16 73
4 13 21 83 42 111
5 17 16 90 36 89
7 10 21 87 41 107
8 13 26 77 34 92
9 25 29 83 22 86
10 3 12 114 30 93
11 9 13 89 48 121
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antigenicity of this peptide can be easily determined. For
instance, when the QD-labeled peptides are mixed with
the standard antibody in solution, if the peptides have
antigenicity, they can bind with antibodies rapidly. The
formations of antigen-antibody complex slow the rota-
tion of the fluorescent tracer and thereby increase the
polarization of the emitted light compared with only
peptides existing in solution. On the other hand, the
polarization has no change if the peptides have no anti-
genicity. In other words, a high FP value represents a
strong antigenicity of peptides, and a low value repre-
sents a weak antigenicity of peptides after FP measure.
When the peptides reacted with standard antibody-
positive serum, in this report, the measured FP values of
the 10 of 11 HBV synthetic peptides were between 200
and 250 mP, far higher than the FP values of the pep-
tides that reacted with the standard antibody-negative
serum, which were only about 150 to 170 mP, and these
peptides may have antigenicity.
In order to optimize the FP assay used in detecting
the interaction of antigenic peptide and antibody, we
investigated the effects of different concentrations of
fluorophore-labeled peptides, different dilution times of
serum samples, and different incubation times of antigen-
antibody mixture on FP assay. The obtained optimal
factors are as follows: 1 nmol/L of fluorophore-labeled
peptides, 1:25 of dilution times of serum samples, and
15 min of incubation time of antigen-antibody mixture.
The established FP assay not only can be used to
identify the antigenicity of peptides with standard
antibody, but can also be used to detect antibodies in
serum samples with known antigenic peptides because
the usages of FP assay in the two aspects share the
same principle and procedures. By analyzing the anti-
body levels against 10 antigenic peptides in 159 anti-
HBV surface antigen-positive antiserum using FP
assay, we found that the antibody levels against nos.
1, 10, and 11 antigenic peptides were higher than
those against other peptides or the antibodies against
these peptides widely existed in 159 samples. This indi-
cates that the three peptides may be immunodominant
among 159 samples.
Based on the three dominant antigenic peptides, we also
study the application of FP assay in detecting HBV infec-
tion. The FP assay data were subjected to ROC curve ana-
lysis which estimates the sensitivity and specificity of a
test at every possible cutoff point and provides a measure
of test accuracy. The ROC curve that was obtained from
the analysis of the FP assay results indicated that the three
dominant antigenic peptides are accurate indicators of
HBV infection. The antibody-positive ratio was 51.9%, an-
alyzed using the three antigenic peptides; the sensitivity
and specificity estimates at the cutoff point 77 mP were
85.4% and 98.6%, respectively.
Conclusions
In conclusion, homogeneous QD-based FP assay offers
several advantages in analyzing the interaction of peptide
antigen and antibody. This assay is a single-step primary
binding assay using a single reagent - the QD-labeled
antigenic peptides. The assay can be completed in a few
minutes. Secondly, FP assay requires no repetitive wash-
ing procedures to remove unbound reactants. This also
decreases the assay time considerably. In addition, the
outstanding optical quality of QDs in photostability
makes them an excellent fluorescent reporter. Due to
the simple and rapid manipulations and high sensitivity
and specificity, FP assay is very suitable for high-
throughput screening of antigenic peptides and screening
of immunodominant epitopes. The technical simplicity,
rapid speed, and low cost of this assay make it very at-
tractive in specific antibody detection and clinic sero-
logical tests of infectious diseases. In one word, FP assay
has great applied potential in epitope mapping, vaccine
designing, or clinical disease diagnosis in the future.
Additional file
Additional file 1: Figure S1. Characterization of synthesized CdTe
nanocrystals by XRD and HR-TEM. (A) Typical XRD patterns of prepared
CdTe nanocrystals. (B) HR-TEM image shows that the synthesized CdTe
nanocrystals are almost 3 nm in diameter.
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